Cell replacement therapy for Parkinson's disease: How close are we to the clinic?

Expert Review of Neurotherapeutics

Volumn 11, Issue 9, 2011, Pages 1325-1339

  Ganz, Javier ^a   Lev, Nirit ^a   Melamed, Eldad ^a   Offen, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

cell therapy; dopaminergic neurons; embryonic stem cells; induced pluripotent stem cells; mesenchymal stem cells; neural stem cells; Parkinson's disease; regeneration; stem cells; transplantation

Indexed keywords

CARCINOGENESIS; CELL THERAPY; DOPAMINERGIC NERVE CELL; DYSKINESIA; EMBRYONIC STEM CELL; MESENCHYMAL STEM CELL; NEURAL STEM CELL; PARKINSON DISEASE; REVIEW; SUBSTITUTION THERAPY;

CELL DIFFERENTIATION; CELL TRANSPLANTATION; DOPAMINERGIC NEURONS; HUMANS; PARKINSON DISEASE; STEM CELLS;

EID: 80052233023     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.74     Document Type: Review

References (140)

1. Poewe W. The natural history of Parkinson's disease. J. Neurol. 253(S7), vii2-vii6 (2006).
2. Arenas E. Towards stem cell replacement therapies for Parkinson's disease. Biochem. Biophys. Res. Commun. 396(1), 152-156 (2010).
3. Arias-Carrión O, Yuan TF. Autologous neural stem cell transplantation: A new treatment option for Parkinson's disease? Med. Hypotheses 73(5), 757-759 (2009).
4. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351(24), 2498-2508 (2004).
5. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders - time for clinical translation? J. Clin. Invest. 120(1), 29-40 (2010).
6. Yokochi M. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 1), S25-S30 (2009).
7. Olson L, Seiger A. Brain tissue transplanted to the anterior chamber of the eye. 1. Fluorescence histochemistry of immature catecholamine and 5-hydroxytryptamine neurons reinnervating the rat iris. Z. Zellforsch. Mikrosk. Anat. 135(2), 175-194 (1972).
8. Seiger A, Olson L, Farnebo LO. Brain tissue transplanted to the anterior chamber of the eye. 4. Drug-modulated transmitter release in central monoamine nerve terminals lacking normal postsynaptic receptors. Cell Tissue Res. 165(2), 157-170 (1976).
9. Hoffer B, Olson L, Seiger A, Bloom F. Formation of a functional adrenergic input to intraocular cerebellar grafts: Ingrowth of inhibitory sympathetic fibers. J. Neurobiol. 6(6), 565-585 (1975).
10. Freed WJ, Perlow MJ, Karoum F et al. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: Long-term behavioral, biochemical, and histochemical studies. Ann. Neurol. 8(5), 510-519 (1980). .. This work, among others, has settled the basis of cell replacement therapy for Parkinson's disease (PD), concluding that substantia nigra grafts can become permanent, functional constituents of the brains of host animals with prior substantia nigra lesions. (Pubitemid 11209236)
11. Björklund A, Stenevi U, Svendgaard N. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path. Nature 262(5571), 787-790 (1976).
12. Stenevi U, Björklund A. Transplantation techniques for the study of regeneration in the central nervous system. Prog. Brain Res. 48, 101-112 (1978).
13. Stenevi U, Björklund A, Svendgaard NA. Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival. Brain Res. 114(1), 1-20 (1976).
14. Wakeman DR, Dodiya HB, Kordower JH. Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J. Med. 78(1), 126-158 (2011).
15. Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD. Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol. Scand. Suppl. 522, 39-47 (1983). (Pubitemid 14197364)
16. Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol. Scand. Suppl. 522, 29-37 (1983). (Pubitemid 14197363)
17. Björklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions. I. Introduction and general methods of preparation. Acta Physiol. Scand. Suppl. 522, 1-7 (1983). (Pubitemid 14197361)
18. Björklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol. Scand. Suppl. 522, 9-18 (1983). (Pubitemid 14153752)
19. Brundin P, Isacson O, Gage FH, Björklund A. Intrastriatal grafting of dopamine-containing neuronal cell suspensions: Effects of mixing with target or non-target cells. Brain Res. 389(1-2), 77-84 (1986). (Pubitemid 16181554)
20. Brundin P, Nilsson OG, Strecker RE et al. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp. Brain Res. 65(1), 235-240 (1986). (Pubitemid 17004013)
21. Brundin P, Björklund A. Survival, growth and function of dopaminergic neurons grafted to the brain. Prog. Brain Res. 71, 293-308 (1987).
22. Freed WJ, Morihisa JM, Spoor E et al. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour. Nature 292(5821), 351-352 (1981). (Pubitemid 11050339)
23. Backlund EO, Granberg PO, Hamberger B et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62(2), 169-173 (1985). (Pubitemid 15159941)
24. Madrazo I, Drucker-Colín R, Díaz V et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 316(14), 831-834 (1987). .. Reported that autografting of the adrenal medulla to the right caudate nucleus was associated with a marked improvement in the signs of PD in two patients. (Pubitemid 17042000)
25. Morihisa JM, Nakamura RK, Freed WJ, Mishkin M, Wyatt RJ. Adrenal medulla grafts survive and exhibit catecholamine-specific fluorescence in the primate brain. Exp. Neurol. 84(3), 643-653 (1984). (Pubitemid 14120152)
26. Plunkett RJ, Bankiewicz KS, Cummins AC et al. Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. J. Neurosurg. 73(6), 918-926 (1990).
27. Goetz CG, Olanow CW, Koller WC et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N. Engl. J. Med. 320(6), 337-341 (1989). (Pubitemid 19106868)
28. Vidaltamayo R, Bargas J, Covarrubias L et al. Stem cell therapy for Parkinson's disease: A road map for a successful future. Stem Cells Dev. 19(3), 311-320 (2010).
29. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344(10), 710-719 (2001). .. Reported that human embryonic dopamine neuron transplants survive in patients with severe PD and result in some clinical benefit in younger, but not older, patients. (Pubitemid 32204988)
30. Bjorklund LM, Sánchez-Pernaute R, Chung S et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl Acad. Sci. USA 99(4), 2344-2349 (2002). (Pubitemid 34169063)
31. O'Keeffe FE, Scott SA, Tyers P et al. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain 131(Pt 3), 630-641 (2008). . Demonstrated that induced pluripotent stem cells can be induced to differentiate into dopamine neurons of midbrain character and were able to improve behavior in a rat model of PD upon transplantation into the adult brain. (Pubitemid 351294721)
32. Wernig M, Zhao J-P, Pruszak J et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl Acad. Sci. USA 105(15), 5856-5861 (2008). (Pubitemid 351758462)
33. Dezawa M, Kanno H, Hoshino M et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J. Clin. Invest. 113(12), 1701-1710 (2004). (Pubitemid 39071662)
34. Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J. Neurochem. 107(1), 141-151 (2008).
35. Murrell W, Wetzig A, Donnellan M et al. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease. Stem Cells 26(8), 2183-2192 (2008).
36. Yasuhara T, Matsukawa N, Hara K et al. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J. Neurosci. 26(48), 12497-12511 (2006). (Pubitemid 44864515)
37. Kim J-H, Auerbach JM, Rodríguez-Gómez JA et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418(6893), 50-56 (2002). (Pubitemid 34742566)
38. Cai J, Yang M, Poremsky E et al. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev. 19(7), 1017-1023 (2010).
39. Levy YS, Bahat-Stroomza M, Barzilay R et al. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy 10(4), 340-352 (2008). (Pubitemid 351983158)
40. Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol. Sci. 30(5), 260-267 (2009).
41. Galpern WR, Burns LH, Deacon TW, Dinsmore J, Isacson O. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: Functional recovery and graft morphology. Exp. Neurol. 140(1), 1-13 (1996). (Pubitemid 26266588)
42. Fink JS, Schumacher JM, Ellias SL et al. Porcine xenografts in Parkinson's disease and Huntington's disease patients: Preliminary results. Cell Transplant. 9(2), 273-278 (2000). (Pubitemid 30252692)
43. Fitzpatrick KM, Raschke J, Emborg ME. Cell-based therapies for Parkinson's disease: Past, present, and future. Antioxid. Redox Signal. 11(9), 2189-2208 (2009).
44. Roitberg B, Urbaniak K, Emborg M. Cell transplantation for Parkinson's disease. Neurol. Res. 26(4), 355-362 (2004). (Pubitemid 38758456)
45. Bakay RAE, Raiser CD, Stover NP et al. Implantation of Spheramine in advanced Parkinson's disease (PD). Front. Biosci. 9, 592-602 (2004). (Pubitemid 39043737)
46. Doudet DJ, Cornfeldt ML, Honey CR, Schweikert AW, Allen RC. PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease. Exp. Neurol. 189(2), 361-368 (2004). (Pubitemid 39221828)
47. Stover NP, Bakay RAE, Subramanian T et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch. Neurol. 62(12), 1833-1837 (2005). (Pubitemid 41785076)
48. Madrazo I, León V, Torres C et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N. Engl. J. Med. 318(1), 51 (1988). (Pubitemid 18025482)
49. Nakao N, Itakura T, Uematsu Y, Komai N. Transplantation of cultured sympathetic ganglionic neurons into parkinsonian rat brain: Survival and function of graft. Acta Neurochir. (Wien.) 133(1-2), 61-67 (1995).
50. Itakura T, Uematsu Y, Nakao N, Nakai E, Nakai K. Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease. Long-term follow-up of 35 cases. Stereotact. Funct. Neurosurg. 69(1-4 Pt 2), 112-115 (1997). (Pubitemid 28305428)
51. Gonzalez C, Almaraz L, Obeso A, Rigual R. Carotid body chemoreceptors: From natural stimuli to sensory discharges. Physiol. Rev. 74(4), 829-898 (1994). (Pubitemid 24328941)
52. Hao G, Yao Y, Wang J et al. Intrastriatal grafting of glomus cells ameliorates behavioral defects of Parkinsonian rats. Physiol. Behav. 77(4-5), 519-525 (2002). (Pubitemid 36084395)
53. Luquin MR, Montoro RJ, Guillén J et al. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 22(4), 743-750 (1999). (Pubitemid 29203497)
54. Arjona V, Mínguez-Castellanos A, Montoro RJ et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 53(2), 321-328; discussion 328-330 (2003).
55. Emsley JG, Mitchell BD, Kempermann G, Macklis JD. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog. Neurobiol. 75(5), 321-341 (2005). (Pubitemid 40733268)
56. Gage FH, Ray J, Fisher LJ. Isolation, characterization, and use of stem cells from the CNS. Annu. Rev. Neurosci. 18, 159-192 (1995).
57. Weiss S, Dunne C, Hewson J et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J. Neurosci. 16(23), 7599-7609 (1996). (Pubitemid 26389699)
58. McKay R. Stem cells in the central nervous system. Science 276(5309), 66-71 (1997).
59. Gage FH. Mammalian neural stem cells. Science 287(5457), 1433-1438 (2000). (Pubitemid 30127128)
60. Arsenijevic Y, Villemure JG, Brunet JF et al. Isolation of multipotent neural precursors residing in the cortex of the adult human brain. Exp. Neurol. 170(1), 48-62 (2001). (Pubitemid 32641773)
61. Meyer AK, Maisel M, Hermann A, Stirl K, Storch A. Restorative approaches in Parkinson's Disease: Which cell type wins the race? J. Neurol. Sci. 289(1-2), 93-103 (2010).
62. Svendsen CN, Caldwell MA, Shen J et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp. Neurol. 148(1), 135-146 (1997). (Pubitemid 127445121)
63. Parish CL, Castelo-Branco G, Rawal N et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J. Clin. Invest. 118(1), 149-160 (2008).
64. Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat. Neurosci. 1(4), 290-295 (1998).
65. Jensen P, Pedersen EG, Zimmer J, Widmer HR, Meyer M. Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease. Brain Res. 1218, 13-20 (2008).
66. Papanikolaou T, Lennington JB, Betz A et al. In vitro generation of dopaminergic neurons from adult subventricular zone neural progenitor cells. Stem Cells Dev. 17(1), 157-172 (2008). (Pubitemid 351271612)
67. Shim J-W, Park C-H, Bae Y-C et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem Cells 25(5), 1252-1262 (2007). (Pubitemid 46684885)
68. Kim HJ. Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons. Biochim. Biophys. Acta. 1812(1), 1-11 (2011).
69. Greco SJ, Rameshwar P. Recent advances and novel approaches in deriving neurons from stem cells. Mol. Biosyst. 6(2), 324-328 (2010).
70. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145-1147 (1998). (Pubitemid 28516247)
71. Kawasaki H, Mizuseki K, Nishikawa S et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28(1), 31-40 (2000).
72. Roy NS, Cleren C, Singh SK et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12(11), 1259-1268 (2006). (Pubitemid 44706928)
73. Hwang DY, Kim DS, Kim DW. Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: Current state and problems. J. Cell. Biochem. 109(2), 292-301 (2010).
74. Carpenter MK, Inokuma MS, Denham J et al. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp. Neurol. 172(2), 383-397 (2001). (Pubitemid 34075087)
75. Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat. Biotechnol. 18(6), 675-679 (2000). (Pubitemid 30415305)
76. Perrier AL, Tabar V, Barberi T et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl Acad. Sci. USA 101(34), 12543-12548 (2004). (Pubitemid 39122060)
77. Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale. Nat. Protoc. 3(12), 1888-1894 (2008). . Reported a detailed differentiation protocol using embryonic stem cells, in which a high yield of functional dopaminergic neurons was achieved.
78. Tondreau T, Lagneaux L, Dejeneffe M et al. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 72(7), 319-326 (2004). (Pubitemid 41702124)
79. Blondheim NR, Levy YS, Ben-Zur T et al. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev. 15(2), 141-164 (2006). (Pubitemid 43726495)
80. Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells 24(4), 1054-1064 (2006). (Pubitemid 44464738)
81. Minguell JJ, Fierro FA, Epuñan MJ, Erices AA, Sierralta WD. Nonstimulated human uncommitted mesenchymal stem cells express cell markers of mesenchymal and neural lineages. Stem Cells Dev. 14(4), 408-414 (2005). (Pubitemid 41243704)
82. Li Y, Chen J, Wang L et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci. Lett. 316(2), 67-70 (2001). (Pubitemid 34001662)
83. Tropel P, Platet N, Platel JC et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 24(12), 2868-2876 (2006). (Pubitemid 46053023)
84. Wislet-Gendebien S, Hans G, Leprince P et al. Plasticity of cultured mesenchymal stem cells: Switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 23(3), 392-402 (2005). (Pubitemid 40404458)
85. Cho KJ, Trzaska KA, Greco SJ et al. Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 a. Stem Cells. 23(3), 383-391 (2005). (Pubitemid 40404457)
86. Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D. Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells Dev. 18(4), 591-601 (2009).
87. Trzaska KA, Kuzhikandathil EV, Rameshwar P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 25(11), 2797-2808 (2007). (Pubitemid 350127864)
88. Trzaska KA, Reddy BY, Munoz JL et al. Loss of RE-1 silencing factor in mesenchymal stem cell-derived dopamine progenitors induces functional maturity. Mol. Cell. Neurosci. 39(2), 285-290 (2008).
89. Trzaska KA, King CC, Li KY et al. Brain-derived neurotrophic factor facilitates maturation of mesenchymal stem cell-derived dopamine progenitors to functional neurons. J. Neurochem. 110(3), 1058-1069 (2009).
90. Barzilay R, Kan I, Ben-Zur T et al. Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev. 17(3), 547-554 (2008). (Pubitemid 351948195)
91. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006). (Pubitemid 44233629)
92. Park I-H, Arora N, Huo H et al. Disease-specific induced pluripotent stem cells. Cell 134(5), 877-886 (2008).
93. Soldner F, Hockemeyer D, Beard C et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5), 964-977 (2009).
94. Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature 460(7259), 1085-1086 (2009).
95. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14(5), 504-506 (2008). .. Reported that 14 years after transplantation into the striatum of an individual with PD, grafted nigral neurons were found to have Lewy body-like inclusions that stained positively for a-synuclein and ubiquitin, and to have reduced immunostaining for dopamine transporter. (Pubitemid 351655212)
96. Vierbuchen T, Ostermeier A, Pang ZP et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463(7284), 1035-1041 (2010).
97. Hynes M, Porter JA, Chiang C et al. Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron 15(1), 35-44 (1995).
98. Wang MZ, Jin P, Bumcrot DA et al. Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nat. Med. 1(11), 1184-1188 (1995).
99. Ye W, Shimamura K, Rubenstein JL, Hynes MA, Rosenthal A. FGF and SHH signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 93(5), 755-766 (1998). (Pubitemid 28257582)
100. Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet. 13(4), 157-162 (1997). (Pubitemid 27191521)
101. Castelo-Branco G, Wagner J, Rodriguez FJ et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl Acad. Sci. USA 100(22), 12747-12752 (2003). (Pubitemid 37339970)
102. McMahon AP, Bradley A. The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell 62(6), 1073-1085 (1990).
103. Danielian PS, McMahon AP. Engrailed-1 as a target of the Wnt-1 signalling pathway in vertebrate midbrain development. Nature 383(6598), 332-334 (1996). (Pubitemid 26321761)
104. Tio M, Tan KH, Lee W, Wang TT, Udolph G. Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells. PLoS One 5(2), e9398 (2010).
105. Smidt MP, Burbach JPH. How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 8(1), 21-32 (2007). (Pubitemid 46011996)
106. Andersson E, Jensen JB, Parmar M, Guillemot F, Björklund A. Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2. Development 133(3), 507-516 (2006). (Pubitemid 43273836)
107. Saucedo-Cardenas O, Quintana-Hau JD, Le WD et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl Acad. Sci. USA 95(7), 4013-4018 (1998). (Pubitemid 28173245)
108. Smits SM, Ponnio T, Conneely OM, Burbach JPH, Smidt MP. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur. J. Neurosci. 18(7), 1731-1738 (2003). (Pubitemid 37372357)
109. Martinat C, Bacci J-J, Leete T et al. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc. Natl Acad. Sci. USA 103(8), 2874-2879 (2006).
110. Lee HS, Bae EJ, Yi SH et al. Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival. Stem Cells 28(3), 501-512 (2010).
111. Nakatani T, Kumai M, Mizuhara E, Minaki Y, Ono Y. Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control of floor plate cell differentiation in the developing mesencephalon. Dev. Biol. 339(1), 101-113 (2010).
112. Lindvall O, Rehncrona S, Brundin P et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46(6), 615-631 (1989). (Pubitemid 19150940)
113. Barker R, Dunnett S. The biology and behaviour of intracerebral adrenal transplants in animals and man. Rev. Neurosci. 4(2), 113-146 (1993). (Pubitemid 23223668)
114. Lindvall O, Brundin P, Widner H et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247(4942), 574-577 (1990).
115. Widner H, Tetrud J, Rehncrona S et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). N. Engl. J. Med. 327(22), 1556-1563 (1992).
116. Freed CR, Breeze RE, Rosenberg NL et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327(22), 1549-1555 (1992).
117. Spencer DD, Robbins RJ, Naftolin F et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N. Engl. J. Med. 327(22), 1541-1548 (1992).
118. Peschanski M, Defer G, N'Guyen JP et al. Bilateral motor improvement and alteration of l-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117(Pt 3), 487-499 (1994). (Pubitemid 24225897)
119. Wenning GK, Odin P, Morrish P et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42(1), 95-107 (1997). (Pubitemid 27304785)
120. Hauser RA, Freeman TB, Snow BJ et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 56(2), 179-187 (1999). (Pubitemid 29076182)
121. Brundin P, Pogarell O, Hagell P et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123(Pt 7), 1380-1390 (2000). (Pubitemid 30420938)
122. Kordower JH, Rosenstein JM, Collier TJ et al. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370(2), 203-230 (1996). (Pubitemid 26227146)
123. Piccini P, Brooks DJ, Björklund A et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2(12), 1137-1140 (1999). (Pubitemid 30126374)
124. Piccini P, Lindvall O, Björklund A et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 48(5), 689-695 (2000).
125. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Prog. Brain Res. 184, 265-294 (2010).
126. Clarkson ED, Zawada WM, Adams FS, Bell KP, Freed CR. Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats. Brain Res. 806(1), 60-68 (1998). (Pubitemid 29009574)
127. Ma Y, Tang C, Chaly T et al. Dopamine cell implantation in Parkinson's disease: Long-term clinical and 18F-FDOPA PET outcomes. J. Nucl. Med. 51(1), 7-15 (2010).
128. Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54(3), 403-414 (2003). (Pubitemid 37072046)
129. Freeman TB, Olanow CW, Hauser RA et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neurol. 38(3), 379-388 (1995).
130. Olanow CW, Freeman T, Kordower J. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 345(2), 146; author reply 147 (2001).
131. Ma Y, Feigin A, Dhawan V et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Ann. Neurol. 52(5), 628-634 (2002). (Pubitemid 35246867)
132. Politis M. Dyskinesias after neural transplantation in Parkinson's disease: What do we know and what is next? BMC Med. 8, 80 (2010).
133. Hagell P, Piccini P, Björklund A et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5(7), 627-628 (2002). (Pubitemid 34742975)
134. Hagell P, Cenci MA. Dyskinesias and dopamine cell replacement in Parkinson's disease: A clinical perspective. Brain Res. Bull. 68(1-2), 4-15 (2005). (Pubitemid 41698871)
135. Piccini P, Pavese N, Hagell P et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128(Pt 12), 2977-2986 (2005). (Pubitemid 41746650)
136. Politis M, Wu K, Loane C et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2(38), 38ra46 (2010).
137. Mendez I, Viñuela A, Astradsson A et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14(5), 507-509 (2008). (Pubitemid 351655215)
138. Li JY, Englund E, Holton JL et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14(5), 501-503 (2008). (Pubitemid 351655211)
139. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Mov. Disord. 23(16), 2303-2306 (2008).
140. Li JY, Englund E, Widner H et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25(8), 1091-1096 (2010).